When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk is planning to open an artificial ... In September, for example, the company signed an agreement with US start-up Valo Health to apply its AI-powered drug discovery engine to find ...

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn. Artificial intelligence (AI) has long promised ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

Danish healthcare company Novo Nordisk A/S (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a ...

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients ...

Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...

Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's ...

This page features the latest news about the Novo Nordisk B stock. Deutsche Bank cuts Novo Nordisk stock target, keeps Buy rating on Q3 results On Thursday, an analyst from Deutsche Bank (ETR ...

Novo Nordisk's (CO:NOVOb) top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a... Investing.com – Denmark stocks were lower after ...